Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2010

View Archived Issues

HSP 90 inhibitors show potent activity in preclinical models of CRPC

Merck & Co. identifies new gamma-secretase modulators

New PI3K-gamma inhibitors disclosed by Cellzome

ArQule's ARQ-197 shows promise in phase I/II trials in solid tumors

GlaxoSmithKline claims new orexin receptor antagonists

Belgian scientists claim new inhibitors of Flaviviridae replication

CVX-060 MAb evaluated in solid tumors in first-in-human trial

SF-353 exhibits antidepressant effects in preclinical tests

Open-label, extension-phase data support long-term use of rotigotine in RLS

Preclinical data support clinical evaluation of apadenoson in sickle cell anemia

Clinical trial of LTX-315/GV-1001 cancer therapy set to begin

Salix submits NDA to FDA for Xifaxan

Osta Biotechnologies discloses preclinical data on OB-28 in melanoma

FDA grants marketing clearance for Xpert SA Nasal Complete

Interim phase IIb data show safety and tolerability of RG-7128 in hepatitis C

FDA delays phase II trial of CH-4051 in rheumatoid arthritis

Rilonacept meets primary endpoint in Regeneron's phase III trial in gout

UCB and Wilex strengthen strategic alliance for oncology projects

HGS reports phase II data on mapatumumab in advanced multiple myeloma

CoLucid presents trial data showing efficacy of oral lasmiditan

Safety trial of ARV vaginal ring to prevent HIV infection starts in Africa

Revotar begins phase II trial of inhaled bimosiamose in COPD

S*BIO completes enrollment in phase II SB-1518 trials in myelofibrosis

Astellas acquires OSI Pharmaceuticals

FDA advisory committee recommends approval of fingolimod for relapsing MS

Blood estradiol identified as putative biomarker for testicular mature teratoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...